|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02633 JACOBSON PHARMA
Nominal 
1.290 +0.020 (+1.575%) | 2025/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/03 HKD(K$) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | |
| Turnover | 766,553 | -5.364% | 1,576,897 | 1,467,798 | 1,785,579 | 1,595,543 |
| Cost of Sales | (428,750) | -6.495% | (883,958) | (847,323) | (1,038,407) | (975,021) |
| Gross Profit | 337,803 | -3.889% | 692,939 | 620,475 | 747,172 | 620,522 |
| 2025/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/03 HKD(K$) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 3,061 | 2272.868% | 398 | 165 | (3,560) | (3,768) | |
| Profit / (Loss) before Taxation | 173,535 | -1.050% | 373,626 | 254,583 | 339,755 | 231,433 | |
| Taxation | (31,500) | -10.223% | (72,793) | (44,414) | (56,546) | (43,728) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | 52,392 | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | (23,810) | (32,165) | (10,039) | |
| Others | -- | -- | -- | 28,217 | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 142,035 | 1.244% | 300,833 | 266,968 | 251,044 | 177,666 | |
| 2025/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2025/03 HKD(K$) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | |
| Net Finance Costs / (Income) | 8,521 | -37.465% | 26,659 | 54,702 | 49,298 | 23,798 |
| Depreciation & Amortisation | 76,533 | 7.093% | 143,871 | 141,823 | 184,460 | 192,597 |
| Directors' Emoluments | -- | -- | 29,633 | 31,653 | 27,148 | 10,886 |
| 2025/09 - Interim | %Chg (Compare to Interim) | 2025/03 | 2024/03 | 2023/03 | 2022/03 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/09 - Interim | %Chg (Compare to Interim) | 2025/03 | 2024/03 | 2023/03 | 2022/03 | |
| EPS (cts) | 7.120 | 0.707% | 15.150 | 13.900 | 13.130 | 9.270 |
| DPS (cts) | 4.250 | -- | 15.000 | 5.500 | 5.180 | 3.880 |
| Dividend Payout Ratio (%) | 59.691% | -- | 99.010% | 39.568% | 39.452% | 41.855% |
| Cash flow per share ($) | -- | -- | 0.265 | 0.252 | 0.330 | 0.212 |
| NBV per share ($) | 1.117 | -- | 1.226 | 1.186 | 1.415 | 1.288 |
| Remarks: | Real time quote last updated: 12/12/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | HKD 142,035 |
| %Change | 1.244% |
| EPS / (LPS) | HKD 0.071 |
| NBV Per Share ($) | HKD 1.117 |